--- title: "Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.4% - Time to Buy?" type: "News" locale: "en" url: "https://longbridge.com/en/news/293058011.md" description: "Rapport Therapeutics (NASDAQ:RAPP) shares rose 5.4% to $42.09, with trading volume significantly below average. Analysts maintain a 'Moderate Buy' consensus with an average price target of $57.86, citing recent earnings beats and positive ratings from firms like Citigroup and BTIG. Meanwhile, insider Rock Ventures sold shares, while several hedge funds increased their positions in the first quarter." datetime: "2026-07-17T16:00:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/293058011.md) - [en](https://longbridge.com/en/news/293058011.md) - [zh-HK](https://longbridge.com/zh-HK/news/293058011.md) --- # Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.4% - Time to Buy? Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP - Get Free Report) were up 5.4% during trading on Friday . The company traded as high as $41.10 and last traded at $42.09. 30,549 shares changed hands during trading, a decline of 91% from the average daily volume of 355,580 shares. The stock had previously closed at $39.93. Get **Rapport Therapeutics** alerts: ## Wall Street Analysts Forecast Growth - Analysts Can't Get Enough of These Little-Known Biopharma Stocks Several research firms have commented on RAPP. Citigroup reiterated a "market outperform" rating on shares of Rapport Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings restated a "sell (d-)" rating on shares of Rapport Therapeutics in a research note on Tuesday, April 21st. BTIG Research reaffirmed a "buy" rating and set a $65.00 target price on shares of Rapport Therapeutics in a report on Thursday. Wall Street Zen upgraded shares of Rapport Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 9th. Finally, Leerink Partners assumed coverage on shares of Rapport Therapeutics in a research note on Wednesday, June 24th. They issued an "outperform" rating and a $52.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Rapport Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $57.86. **Read Our Latest Stock Analysis on Rapport Therapeutics** ## Rapport Therapeutics Stock Performance The firm has a market capitalization of $2.02 billion, a price-to-earnings ratio of -16.15 and a beta of 0.94. The company has a fifty day moving average of $38.33 and a two-hundred day moving average of $33.05. Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.14. The firm had revenue of $20.00 million during the quarter, compared to analyst estimates of $7.50 million. Equities analysts forecast that Rapport Therapeutics, Inc. will post -3.25 EPS for the current year. ## Insider Activity In other news, major shareholder Rock Ventures V. L.P. Third sold 18,572 shares of the business's stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $40.05, for a total value of $743,808.60. Following the completion of the sale, the insider owned 6,280,525 shares of the company's stock, valued at approximately $251,535,026.25. The trade was a 0.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 428,703 shares of company stock valued at $17,215,252 over the last three months. Insiders own 12.48% of the company's stock. ## Hedge Funds Weigh In On Rapport Therapeutics Hedge funds have recently bought and sold shares of the business. KBC Group NV bought a new stake in Rapport Therapeutics in the 1st quarter valued at about $30,000. Meeder Asset Management Inc. acquired a new position in shares of Rapport Therapeutics during the 4th quarter worth approximately $37,000. Russell Investments Group Ltd. bought a new position in shares of Rapport Therapeutics during the third quarter worth approximately $43,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Rapport Therapeutics by 64.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company's stock worth $70,000 after purchasing an additional 905 shares during the period. Finally, Wilmington Savings Fund Society FSB acquired a new stake in shares of Rapport Therapeutics in the third quarter valued at approximately $143,000. ## Rapport Therapeutics Company Profile (Get Free Report) Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology. Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation. ## Read More - Five stocks we like better than Rapport Therapeutics - TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident - GE Aerospace Faces a Prove-It Moment in Q2 Earnings - Sandisk: What the Chart Is Trying to Tell Us - 3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Rapport Therapeutics Right Now? Before you consider Rapport Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list. While Rapport Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [RAPP.US](https://longbridge.com/en/quote/RAPP.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [WSFS.US](https://longbridge.com/en/quote/WSFS.US.md) - [TSM.US](https://longbridge.com/en/quote/TSM.US.md) - [GE.US](https://longbridge.com/en/quote/GE.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) ## Related News & Research - [Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP](https://longbridge.com/en/news/296325369.md) - [Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million](https://longbridge.com/en/news/295706967.md) - [Meet the Newest Stock in the S&P 500. It Soared 424% Since Its 2024 IPO, and It's a Buy Right Now, According to Wall Street](https://longbridge.com/en/news/296149360.md) - [Simon Read Sells 2,778 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock](https://longbridge.com/en/news/296409810.md) - [Elicera Therapeutics names Johan Liwing CEO](https://longbridge.com/en/news/296185226.md)